Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SION

Sionna Therapeutics Inc

Feb 13 • 04:00PM ET

37.52

-0.12 -0.32 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI XBI IWM IBB VXF IWO VTWO SCHA IWC SBIO

Index	RUT	P/E	-	EPS (ttm)	-1.60	Insider Own	43.96%	Shs Outstand	44.46M	Perf Week	3.90%
Market Cap	1.67B	Forward P/E	-	EPS next Y	-2.26	Insider Trans	-9.85%	Shs Float	25.01M	Perf Month	-8.89%
Enterprise Value	1.44B	PEG	-	EPS next Q	-0.54	Inst Own	54.90%	Short Float	12.57%	Perf Quarter	2.57%
Income	-70.68M	P/S	-	EPS this Y	87.52%	Inst Trans	-2.56%	Short Ratio	9.97	Perf Half Y	79.44%
Sales	0.00M	P/B	5.19	EPS next Y	-13.08%	ROA	-26.35%	Short Interest	3.14M	Perf YTD	-8.80%
Book/sh	7.23	P/C	6.74	EPS next 5Y	45.26%	ROE	-28.07%	52W High	45.00 -16.62%	Perf Year	85.01%
Cash/sh	5.56	P/FCF	-	EPS past 3/5Y	-23.81% -	ROIC	-21.45%	52W Low	7.26 417.16%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.75% 8.01%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-22.20%	Oper. Margin	-	ATR (14)	3.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.61	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	44.38	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	25.61	EPS Q/Q	20.90%	SMA20	-6.69%	Beta	4.00	Target Price	46.75
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-7.96%	Rel Volume	1.04	Prev Close	37.64
Employees	41	LT Debt/Eq	0.02	Earnings	Nov 05 BMO	SMA200	33.66%	Avg Volume	315.32K	Price	37.52
IPO	Feb 07, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	5.02% -	Trades		Volume	327,952	Change	-0.32%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-01-25	Downgrade	RBC Capital Mkts	Sector Perform → Underperform	$24
Nov-19-25	Initiated	BTIG Research	Buy	$50
Sep-03-25	Initiated	RBC Capital Mkts	Sector Perform	$22
Sep-03-25	Initiated	Raymond James	Strong Buy	$45
Mar-04-25	Initiated	TD Cowen	Buy
Mar-04-25	Initiated	Stifel	Buy	$32
Mar-04-25	Initiated	Guggenheim	Buy	$45

Feb-04-26 07:00AM	Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.12%
Jan-05-26 07:00AM	Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Nov-24-25 07:00AM	Sionna Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-14-25 06:00PM	Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com) +7.92%
07:00AM	Loading…
Nov-05-25 07:00AM	Sionna Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:00AM	Sionna Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com) -5.63%
Oct-24-25 01:15PM	Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Oct-21-25 07:00AM	Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis (GlobeNewswire) +31.99%
Oct-01-25 04:05PM	Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-15-25 12:00PM	All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy (Zacks)
Sep-09-25 09:55AM	Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High? (Zacks) +13.32%
Sep-08-25 08:00AM	Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer (GlobeNewswire) -9.92%
Aug-27-25 07:00AM	Sionna Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Aug-25-25 07:00AM	Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis (GlobeNewswire)
Aug-11-25 07:00AM	Sionna Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire) +13.36%
Jun-06-25 11:00AM	Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model (GlobeNewswire) +7.42%
Jun-04-25 01:54PM	Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial (Benzinga) +9.12%
07:00AM	Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis (GlobeNewswire)
Jun-03-25 07:00AM	Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 07:00AM	Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference (GlobeNewswire)
May-12-25 07:00AM	Sionna Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-30-25 07:00AM	Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 (GlobeNewswire)
Mar-20-25 07:00AM	Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-15-25 04:43PM	Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:25AM	Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey) -5.04%
Mar-03-25 12:57PM	Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-25-25 05:56AM	Sionna Therapeutics IPO: A strategic shift in the cystic fibrosis market (Pharmaceutical Technology) -13.37%
Feb-24-25 08:00AM	Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
04:43PM	Loading…
Feb-17-25 04:43PM	Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:03PM	Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.04% -8.23%
Feb-06-25 07:51PM	Sionna Therapeutics Prices Upsized Initial Public Offering (GlobeNewswire)
03:13PM	Vertex challenger Sionna prices $191M IPO (BioPharma Dive)

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a robust pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Peter A.	Director	Feb 03 '26	Sale	44.58	29,063	1,295,629	3,530,702	Feb 04 07:43 PM
Thompson Peter A.	Director	Feb 02 '26	Sale	44.57	1,890	84,237	3,559,765	Feb 04 07:43 PM
ORBIMED ADVISORS LLC	Director	Feb 03 '26	Sale	44.58	29,063	1,295,629	3,530,702	Feb 04 07:39 PM
ORBIMED ADVISORS LLC	Director	Feb 02 '26	Sale	44.57	1,890	84,237	3,559,765	Feb 04 07:39 PM
TPG GP A, LLC	10% Owner	Jan 22 '26	Sale	40.00	250,000	10,000,000	6,494,962	Jan 26 05:24 PM
Rise Fund Sling, L.P.	Stockholder	Jan 22 '26	Proposed Sale	41.77	195,667	8,173,011		Jan 22 08:47 PM
Rise Fund Sling II, L.P.	Stockholder	Jan 22 '26	Proposed Sale	41.77	54,333	2,269,489		Jan 22 08:47 PM
ORBIMED ADVISORS LLC	Director	Dec 24 '25	Sale	44.55	33,356	1,486,010	3,561,655	Dec 29 08:44 PM
Thompson Peter A.	Director	Dec 24 '25	Sale	44.55	33,356	1,486,010	3,561,655	Dec 29 08:42 PM
ORBIMED ADVISORS LLC	Director	Dec 17 '25	Sale	44.50	900	40,050	3,595,986	Dec 19 07:29 PM
ORBIMED ADVISORS LLC	Director	Dec 19 '25	Sale	44.49	875	38,929	3,595,011	Dec 19 07:29 PM
ORBIMED ADVISORS LLC	Director	Dec 18 '25	Sale	44.49	100	4,449	3,595,886	Dec 19 07:29 PM
Thompson Peter A.	Director	Dec 17 '25	Sale	44.50	900	40,050	3,595,986	Dec 19 07:24 PM
Thompson Peter A.	Director	Dec 19 '25	Sale	44.49	875	38,929	3,595,011	Dec 19 07:24 PM
Thompson Peter A.	Director	Dec 18 '25	Sale	44.49	100	4,449	3,595,886	Dec 19 07:24 PM
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Option Exercise	6.11	10,250	62,628	10,250	Dec 09 04:57 PM
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Sale	40.52	10,250	415,330	0	Dec 09 04:57 PM
JENNIFER R FITZPATRICK	Officer	Dec 05 '25	Proposed Sale	40.88	10,250	419,020		Dec 05 04:27 PM
ORBIMED ADVISORS LLC	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:45 PM
Thompson Peter A.	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:41 PM
OrbiMed Private Investments VI	Shareholder	Nov 24 '25	Proposed Sale	44.38	1,047,770	46,500,033		Nov 24 08:22 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 21 '25	Sale	39.50	25,183	994,728	159,033	Nov 24 05:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 20 '25	Sale	40.13	5,133	205,975	166,642	Nov 24 05:43 PM
RA Capital Healthcare Fund LP	Director	Nov 21 '25	Proposed Sale	43.66	1,210	52,829		Nov 21 04:24 PM
RA Capital Nexus Fund III, L.P	Director	Nov 21 '25	Proposed Sale	43.66	6,440	281,170		Nov 21 04:21 PM
RA Capital Nexus Fund, L.P.	Director	Nov 21 '25	Proposed Sale	43.66	9,924	433,282		Nov 21 04:19 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 21 '25	Proposed Sale	43.66	7,609	332,209		Nov 21 04:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 20 '25	Proposed Sale	38.94	1,313	51,128		Nov 20 04:40 PM
RA Capital Nexus Fund, L.P.	Director	Nov 20 '25	Proposed Sale	38.94	2,023	78,776		Nov 20 04:35 PM
RA Capital Healthcare Fund LP	Director	Nov 20 '25	Proposed Sale	38.94	246	9,579		Nov 20 04:34 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 20 '25	Proposed Sale	38.94	1,551	60,396		Nov 20 04:30 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 17 '25	Sale	40.59	81,987	3,328,081	184,619	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 19 '25	Sale	40.01	47,442	1,898,173	168,193	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 18 '25	Sale	39.57	6,922	273,904	182,527	Nov 19 08:43 PM
RA Capital Healthcare Fund LP	Director	Nov 19 '25	Proposed Sale	39.12	2,278	89,115		Nov 19 05:21 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 19 '25	Proposed Sale	38.41	14,334	550,568		Nov 19 05:16 PM
RA Capital Nexus Fund, L.P.	Director	Nov 19 '25	Proposed Sale	38.41	18,696	718,113		Nov 19 05:10 PM
RA Capital Nexus Fund III, L.P	Director	Nov 19 '25	Proposed Sale	38.41	12,134	466,066		Nov 19 05:04 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 18 '25	Proposed Sale	39.04	2,092	81,671		Nov 18 05:22 PM
RA Capital Nexus Fund, L.P.	Director	Nov 18 '25	Proposed Sale	39.04	2,728	106,501		Nov 18 05:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 18 '25	Proposed Sale	39.04	1,770	69,100		Nov 18 05:09 PM
RA Capital Healthcare Fund LP	Director	Nov 18 '25	Proposed Sale	39.04	332	12,961		Nov 18 04:58 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 17 '25	Proposed Sale	39.93	24,772	989,146		Nov 17 05:12 PM
RA Capital Nexus Fund, L.P.	Director	Nov 17 '25	Proposed Sale	39.93	32,310	1,290,138		Nov 17 05:04 PM
RA Capital Nexus Fund III, L.P	Director	Nov 17 '25	Proposed Sale	39.93	20,969	837,292		Nov 17 04:56 PM
RA Capital Healthcare Fund LP	Director	Nov 17 '25	Proposed Sale	39.93	3,936	157,164		Nov 17 04:46 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 24 '25	Sale	39.50	311,000	12,284,500	219,867	Oct 28 09:05 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 28 '25	Sale	39.58	62,610	2,478,104	209,391	Oct 28 09:05 PM
RA Capital Nexus Fund III, L.P	Director	Oct 28 '25	Proposed Sale	39.45	17,118	675,305		Oct 28 05:13 PM
RA Capital Healthcare Fund LP	Director	Oct 28 '25	Proposed Sale	39.45	3,624	142,967		Oct 28 05:07 PM
RA Capital Nexus Fund, L.P.	Director	Oct 28 '25	Proposed Sale	39.45	31,392	1,238,414		Oct 28 05:05 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Oct 28 '25	Proposed Sale	39.45	10,476	413,278		Oct 28 04:57 PM
RA Capital Nexus Fund, L.P.	Director	Oct 24 '25	Proposed Sale	39.21	122,271	4,794,246		Oct 24 06:05 PM
RA Capital Nexus Fund III, L.P	Director	Oct 24 '25	Proposed Sale	39.21	66,672	2,614,209		Oct 24 06:00 PM
RA Capital Healthcare Fund LP	Director	Oct 24 '25	Proposed Sale	39.21	14,116	553,488		Oct 24 05:53 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Oct 24 '25	Proposed Sale	39.21	107,941	4,232,367		Oct 24 05:39 PM
Cloonan Michael	President & CEO	Oct 21 '25	Option Exercise	6.11	99,800	609,778	580,875	Oct 22 05:39 PM
Cloonan Michael	President & CEO	Oct 21 '25	Sale	36.26	99,800	3,618,560	547,343	Oct 22 05:39 PM
Booth Bruce	Director	Oct 21 '25	Sale	34.22	88,878	3,041,683	686,567	Oct 21 05:12 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 21 '25	Proposed Sale	32.20	15,418	496,460		Oct 21 04:22 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 21 '25	Proposed Sale	32.20	73,460	2,365,412		Oct 21 04:21 PM
MICHAEL CLOONAN	Director	Oct 21 '25	Proposed Sale	32.20	99,800	3,213,560		Oct 21 04:19 PM
Booth Bruce	Director	Oct 16 '25	Sale	32.35	169,260	5,476,168	722,301	Oct 20 09:39 PM
Booth Bruce	Director	Oct 17 '25	Sale	32.37	61,124	1,978,323	711,697	Oct 20 09:39 PM
Booth Bruce	Director	Oct 20 '25	Sale	32.09	55,985	1,796,611	701,985	Oct 20 09:39 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 20 '25	Proposed Sale	31.93	46,273	1,477,497		Oct 20 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 20 '25	Proposed Sale	31.93	9,712	310,104		Oct 20 04:46 PM
Cloonan Michael	President & CEO	Oct 15 '25	Option Exercise	6.11	14,775	90,275	562,118	Oct 17 05:11 PM
Cloonan Michael	President & CEO	Oct 16 '25	Option Exercise	6.11	10,425	63,697	557,568	Oct 17 05:11 PM
Cloonan Michael	President & CEO	Oct 15 '25	Sale	31.11	14,775	459,662	547,343	Oct 17 05:11 PM
Cloonan Michael	President & CEO	Oct 16 '25	Sale	31.51	10,425	328,491	547,343	Oct 17 05:11 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 17 '25	Proposed Sale	32.71	10,604	346,857		Oct 17 04:27 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 17 '25	Proposed Sale	32.72	50,520	1,653,014		Oct 17 04:27 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 16 '25	Proposed Sale	30.91	139,897	4,324,216		Oct 16 05:01 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 16 '25	Proposed Sale	30.91	29,363	907,610		Oct 16 05:00 PM
MICHAEL CLOONAN	Director	Oct 16 '25	Proposed Sale	30.91	200	6,182		Oct 16 04:34 PM
Booth Bruce	Director	Oct 15 '25	Sale	30.61	115,856	3,545,798	751,664	Oct 15 06:33 PM
Booth Bruce	Director	Oct 13 '25	Sale	30.38	58,232	1,769,101	771,867	Oct 15 06:33 PM
Booth Bruce	Director	Oct 10 '25	Sale	29.98	20,238	606,735	781,969	Oct 15 06:33 PM
Booth Bruce	Director	Oct 14 '25	Sale	29.95	606	18,150	771,762	Oct 15 06:33 PM
MICHAEL CLOONAN	Director	Oct 15 '25	Proposed Sale	29.94	25,000	748,500		Oct 15 04:38 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 13 '25	Proposed Sale	29.42	48,130	1,415,985		Oct 14 04:23 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 13 '25	Proposed Sale	29.42	10,102	297,201		Oct 14 04:22 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 10 '25	Proposed Sale	28.35	3,511	99,537		Oct 10 04:24 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 10 '25	Proposed Sale	28.35	16,727	474,210		Oct 10 04:24 PM
Booth Bruce	Director	Oct 03 '25	Sale	30.00	37,746	1,132,380	787,527	Oct 07 05:00 PM
Booth Bruce	Director	Oct 06 '25	Sale	29.95	11,800	353,410	785,480	Oct 07 05:00 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 06 '25	Proposed Sale	30.01	2,047	61,430		Oct 06 04:51 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 06 '25	Proposed Sale	30.01	9,753	292,688		Oct 06 04:51 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 03 '25	Proposed Sale	29.30	6,548	191,856		Oct 03 04:44 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 03 '25	Proposed Sale	29.30	31,198	914,101		Oct 03 04:44 PM
Booth Bruce	Director	Sep 29 '25	Sale	30.09	66,105	1,989,099	796,259	Oct 01 06:04 PM
Booth Bruce	Director	Sep 30 '25	Sale	30.06	12,388	372,383	794,110	Oct 01 06:04 PM
Booth Bruce	Director	Oct 01 '25	Sale	29.95	200	5,990	794,075	Oct 01 06:04 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 01 '25	Proposed Sale	29.41	165	4,853		Oct 01 04:17 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 01 '25	Proposed Sale	29.41	35	1,029		Oct 01 04:17 PM

Open in Screener

DYN

Dyne Therapeutics Inc

Feb 13 • 04:00PM ET

15.54

-0.46 -2.88 %

Healthcare • Biotechnology • USA • NASD

DYN Dyne Therapeutics Inc daily Stock Chart

Peers: BIIB VRTX CRSP ALNY BMRN RARE NTLA SRPT EDIT BLUE

| Held by: VTI XBI IWM VB VXF VBR IBB VTWO IWN SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.66	Insider Own	26.51%	Shs Outstand	142.61M	Perf Week	-7.50%
Market Cap	2.51B	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-0.03%	Shs Float	118.92M	Perf Month	-10.95%
Enterprise Value	1.84B	PEG	-	EPS next Q	-0.76	Inst Own	87.87%	Short Float	16.14%	Perf Quarter	-16.50%
Income	-423.80M	P/S	-	EPS this Y	-3.91%	Inst Trans	32.82%	Short Ratio	7.70	Perf Half Y	24.32%
Sales	0.00M	P/B	3.20	EPS next Y	7.20%	ROA	-51.81%	Short Interest	19.19M	Perf YTD	-20.55%
Book/sh	4.85	P/C	3.18	EPS next 5Y	4.87%	ROE	-60.66%	52W High	25.00 -37.84%	Perf Year	10.60%
Cash/sh	4.89	P/FCF	-	EPS past 3/5Y	-4.75% -59.45%	ROIC	-52.50%	52W Low	6.36 144.34%	Perf 3Y	16.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.57% 5.92%	Perf 5Y	-16.50%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2.75%	Oper. Margin	-	ATR (14)	1.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.47	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.23	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	13.47	EPS Q/Q	20.87%	SMA20	-10.70%	Beta	1.34	Target Price	39.12
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	-15.82%	Rel Volume	0.36	Prev Close	16.00
Employees	191	LT Debt/Eq	0.17	Earnings	Nov 05 AMC	SMA200	4.58%	Avg Volume	2.49M	Price	15.54
IPO	Sep 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.21% -	Trades		Volume	898,857	Change	-2.88%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform	$40
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy	$35
Jun-24-25	Initiated	Bernstein	Mkt Perform	$13
Jun-11-25	Resumed	Raymond James	Outperform	$37
Jun-02-25	Resumed	Oppenheimer	Outperform	$34
May-29-25	Initiated	Evercore ISI	Outperform	$46
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15

Show Previous Ratings

Jan-27-26 09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-20-26 07:30AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-15-26 11:35AM	Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) (Insider Monkey) -5.90%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 07:30AM	Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.01%
07:30AM	Loading…
Dec-23-25 07:30AM	Dyne Therapeutics Appoints Vikram Karnani to Board of Directors (GlobeNewswire)
Dec-22-25 06:50AM	Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) (Insider Monkey)
Dec-11-25 04:05PM	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
07:44AM	Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial (Insider Monkey)
Dec-10-25 06:20PM	Why Dyne Therapeutics Stock Was a Big Winner on Wednesday (Motley Fool) +6.78%
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
Dec-09-25 09:42PM	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock (GlobeNewswire) -16.94%
06:42PM	Why Dyne Therapeutics Stock Tanked on Tuesday (Motley Fool)
04:54PM	Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More (Motley Fool)
02:22PM	Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate (Insider Monkey)
01:34PM	Loading…
01:34PM	Dyne to seek accelerated approval of DMD drug on Phase I/II data (Clinical Trials Arena)
Dec-08-25 04:02PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +9.47%
03:07PM	Why Dyne Therapeutics Stock Was Blasting Higher Today (Motley Fool)
06:30AM	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 11:00AM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET (GlobeNewswire)
Nov-30-25 12:26AM	Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release (Insider Monkey)
Nov-21-25 03:43PM	Why Dyne Therapeutics Stock Was Crushing it This Week (Motley Fool) +5.27%
Nov-05-25 04:10PM	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -12.89%
Nov-03-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.78%
Oct-28-25 05:24AM	Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger (Insider Monkey)
Oct-27-25 06:17PM	Why Dyne Therapeutics Stock Crushed the Market on Monday (Motley Fool) +41.18%
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Loading…
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
Oct-16-25 04:33PM	Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year (Insider Monkey)
Oct-06-25 06:01PM	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +10.28%
Oct-04-25 04:54PM	Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data (Insider Monkey)
Oct-02-25 04:05PM	Dyne Therapeutics Appoints Brian Posner to its Board of Directors (GlobeNewswire)
Sep-29-25 08:35AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire) -5.93%
Sep-10-25 12:20AM	Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating (Insider Monkey)
Aug-27-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:13AM	Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT (Insider Monkey)
Aug-17-25 11:41PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy (Insider Monkey)
Aug-06-25 12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com) +10.70%
Aug-04-25 07:30AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jul-31-25 09:55AM	Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 04:10PM	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.43%
Jul-16-25 07:00AM	Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer (Business Wire) +12.68%
Jul-11-25 11:27AM	RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT (Insider Monkey)
Jul-02-25 04:01PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-25 09:45PM	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock (GlobeNewswire) -8.82%
04:05PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital (GlobeNewswire)
Jun-24-25 12:46PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101 (Insider Monkey)
Jun-18-25 09:45AM	Dyne at attractive entry point following pullback, says Chardan (TipRanks)
Jun-17-25 07:00AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting (GlobeNewswire) -21.42%
Jun-16-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET (GlobeNewswire)
Jun-05-25 07:30AM	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress (GlobeNewswire)
May-08-25 07:30AM	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +20.16%
Apr-25-25 05:05AM	EC grants orphan drug designation to Dyne Therapeutics DMD therapy (Pharmaceutical Technology)
Apr-24-25 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +14.20% +6.22%
Apr-15-25 07:30AM	Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments (GlobeNewswire) +5.09%
Apr-14-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -11.76%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
04:19PM	Dyne Therapeutics appoints Erick Lucera as CFO (SeekingAlpha)
04:10PM	Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer (GlobeNewswire)
Mar-16-25 07:00PM	Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months (GlobeNewswire)
Mar-12-25 03:05PM	Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks (Benzinga)
01:12PM	BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating (GuruFocus.com)
Mar-11-25 07:30AM	Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-27-25 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-14-25 04:05PM	Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-13-25 09:35AM	After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) (Zacks)
Feb-06-25 09:39AM	Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey) +6.89%
Feb-03-25 07:30AM	Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 09:35AM	Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround (Zacks)
Jan-21-25 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-10-25 06:30AM	Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 (GlobeNewswire) -31.15%
Jan-09-25 07:30AM	Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET (GlobeNewswire) -31.15%
Nov-22-24 06:43AM	Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-12-24 07:30AM	Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:15PM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-09-24 07:30AM	Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases (GlobeNewswire)
Oct-07-24 05:32PM	Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now (Insider Monkey)
Sep-23-24 08:56AM	Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -5.36%
Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga) -30.70%
06:31AM	Dyne Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
06:30AM	Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts (GlobeNewswire)
Aug-29-24 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-24 10:52PM	DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
05:10PM	Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-29-24 08:50AM	Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why (Zacks)
Jul-18-24 12:00PM	What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now? (Zacks)
Jul-12-24 08:50AM	Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-24-24 07:30AM	Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease (GlobeNewswire)
Jun-13-24 04:40PM	Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress (GlobeNewswire)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kerr Douglas	Officer	Dec 05 '25	Proposed Sale	20.72	880	18,231		Dec 05 04:56 PM
Cox John	Officer	Dec 05 '25	Proposed Sale	20.72	2,662	55,150		Dec 05 04:55 PM
Cox John	CEO & President	Dec 05 '25	Sale	20.72	2,662	55,157	196,877	Dec 05 04:11 PM
Kerr Douglas	Chief Medical Officer	Dec 05 '25	Sale	20.72	880	18,234	87,510	Dec 05 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Dec 05 '25	Sale	20.72	144	2,984	94,729	Dec 05 04:08 PM
Cox John	CEO & President	Sep 05 '25	Sale	13.41	2,640	35,402	199,539	Sep 09 04:31 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 04 '25	Sale	13.27	894	11,863	95,017	Sep 08 04:06 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 05 '25	Sale	13.41	144	1,931	94,873	Sep 08 04:06 PM
Kerr Douglas	Chief Medical Officer	Sep 04 '25	Sale	13.27	3,552	47,135	89,263	Sep 08 04:03 PM
Kerr Douglas	Chief Medical Officer	Sep 05 '25	Sale	13.41	873	11,707	88,390	Sep 08 04:03 PM
Cox John	Officer	Sep 05 '25	Proposed Sale	13.41	2,640	35,404		Sep 05 04:14 PM
Kerr Douglas	Officer	Sep 04 '25	Proposed Sale	13.27	4,552	60,402		Sep 04 04:45 PM
Cox John	CEO & President	Jul 14 '25	Buy	9.11	100,000	911,000	242,179	Jul 15 05:11 PM
Scalzo Richard William	Officer	Jun 11 '25	Proposed Sale	14.75	1,330	19,619		Jun 11 04:30 PM
Beskrovnaya Oxana	Officer	Jun 11 '25	Proposed Sale	14.75	2,132	31,449		Jun 11 04:29 PM
Cox John	CEO & President	Jun 05 '25	Sale	13.35	4,060	54,201	142,179	Jun 06 04:07 PM
Kerr Douglas	Chief Medical Officer	Jun 05 '25	Sale	13.35	1,342	17,916	92,815	Jun 06 04:05 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Jun 05 '25	Sale	13.35	146	1,949	95,911	Jun 06 04:03 PM
Kerr Douglas	Officer	Jun 05 '25	Proposed Sale	13.35	1,342	17,911		Jun 05 04:13 PM
Cox John	Officer	Jun 05 '25	Proposed Sale	13.35	4,060	54,186		Jun 05 04:11 PM
Scalzo Richard William	Officer	Jun 05 '25	Proposed Sale	13.35	914	12,198		Jun 05 04:09 PM
Beskrovnaya Oxana	Officer	Jun 05 '25	Proposed Sale	13.35	1,093	14,587		Jun 05 04:07 PM
Scalzo Richard William	Officer	May 16 '25	Proposed Sale	11.82	2,479	29,313		May 16 04:10 PM
Beskrovnaya Oxana	Officer	May 16 '25	Proposed Sale	11.82	2,589	30,614		May 16 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Mar 13 '25	Sale	12.12	143	1,733	96,057	Mar 13 04:13 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '25	Sale	11.38	1,343	15,283	122,330	Mar 13 04:08 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '25	Sale	11.38	2,153	24,501	195,840	Mar 13 04:08 PM
Beskrovnaya Oxana	Officer	Mar 11 '25	Proposed Sale	11.38	2,153	24,493		Mar 11 04:09 PM
Scalzo Richard William	Officer	Mar 11 '25	Proposed Sale	11.38	1,343	15,278		Mar 11 04:08 PM
Kerr Douglas	Chief Medical Officer	Mar 05 '25	Sale	11.83	1,343	15,888	94,157	Mar 07 04:08 PM
Cox John	CEO & President	Mar 05 '25	Sale	11.83	4,061	48,042	146,239	Mar 07 04:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 05 '25	Sale	11.83	917	10,848	123,673	Mar 07 04:06 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 05 '25	Sale	11.83	1,094	12,942	197,993	Mar 07 04:04 PM
Kerr Douglas	Officer	Mar 05 '25	Proposed Sale	11.89	1,343	15,968		Mar 05 04:10 PM
Cox John	Officer	Mar 05 '25	Proposed Sale	11.89	4,067	48,356		Mar 05 04:09 PM
Beskrovnaya Oxana	Officer	Mar 05 '25	Proposed Sale	11.89	1,094	13,007		Mar 05 04:08 PM
Scalzo Richard William	Officer	Mar 05 '25	Proposed Sale	11.89	915	10,879		Mar 05 04:07 PM
Beskrovnaya Oxana	Chief Scientific Officer	Feb 18 '25	Sale	13.95	2,598	36,242	199,087	Feb 25 05:09 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 18 '25	Sale	13.95	2,488	34,708	124,590	Feb 18 05:09 PM
Scalzo Richard William	Officer	Feb 18 '25	Proposed Sale	13.91	2,488	34,608		Feb 18 04:15 PM
Beskrovnaya Oxana	Officer	Feb 18 '25	Proposed Sale	13.91	2,598	36,138		Feb 18 04:14 PM

SION

Sionna Therapeutics Inc

DYN

Dyne Therapeutics Inc

Upgrade your FINVIZ experience